Russia’s public health watchdog Rospotrebnadzor affirmed on Tuesday that the EpiVacCorona COVID-19 vaccine, the second jab that Moscow recorded, has proved a 100% efficacy in the clinical trials.
The evaluation was based on the data collected during the first two phases of the jab’s clinical trial, the statement read.
The vaccine, developed by the Vector Institute, was filed in October and entered the third phase of the trial a month later.
United States National Security Council (NSC) Coordinator for Strategic Communications John Kirby told Al-Jazeera on…
Tunis Court of Appeal confirms the verdict pronounced in the first instance against Ennahdha leader…
Spanish Prime Minister Pedro Sánchez stated on Friday that he would “reveal on Wednesday the…
A patrol affiliated with intelligence units in the National Guard district of Manouba was able…
A middle school in the locality of El Jadida, in the Manouba region, registered the poisoning…
Tabarka National Guard research and investigation brigade carried out a raid on a coral trafficker.…
This website uses cookies.